Biomarin Pharmaceutical (BMRN) Cash from Operations (QoQ) (2009 - 2026)
Biomarin Pharmaceutical (BMRN) Cash from Operations (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Biomarin Pharmaceutical | 11.73 Bn | 9.51 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 121.44% |
| Dec 31, 2025 | -72.97% |
| Sep 30, 2025 | 99.00% |
| Jun 30, 2025 | 6.24% |
| Mar 31, 2025 | -6.05% |
| Dec 31, 2024 | -16.19% |
| Sep 30, 2024 | 86.49% |
| Jun 30, 2024 | 152.84% |
| Mar 31, 2024 | 70.91% |
| Dec 31, 2023 | -79.74% |
| Sep 30, 2023 | 93.61% |
| Jun 30, 2023 | 194.77% |
| Mar 31, 2023 | -1,189.48% |
| Dec 31, 2022 | -95.71% |
| Sep 30, 2022 | 181.58% |
| Jun 30, 2022 | 223.76% |
| Mar 31, 2022 | -506.36% |
| Dec 31, 2021 | -88.48% |
| Sep 30, 2021 | 17.24% |
| Jun 30, 2021 | -27.07% |